Researchers conducted a trial a high-dose flu vaccine — IIV3-HD — with a standard-dose vaccine — IIV3-SD. A total of 31,989 participants were enrolled from 126 research centers in the United States and Canada. Around 15,991 were randomly assigned to receive IIV3-HD and 15,998 to receive IIV3-SD.
According to the study:
• Approximately 1.4 percent of participants in the high-dose group had laboratory-confirmed influenza as compared to 1.9 percent of the standard-dose group.
• At least one serious adverse event during the safety surveillance period was reported by 8.3 percent of the participants in the high-dose group as compared with nine of the participants in the standard-dose group.
• The high-dose vaccine induced significantly higher antibody responses and provided better protection against laboratory-confirmed influenza illness than the standard-dose vaccine.
More articles on quality:
Patient harms up 70% in Massachusetts hospitals
Study: 9 factors associated with SSI after colon procedures
MRSA colonization not limited to nose: Study
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
